Abstract: Lyophilization methods for preparing protein formulations for long-term storage at room temperature or improved stability at refrigeration storage are provided. Specifically, the present application provides lyophilization methods to obtain a target percentage of residual moisture of a lyophilized product, such as 3-5% residual moisture. The secondary drying of the lyophilization can be conducted under controlling rate of desorption under a temperature which is similar to the shelf temperature of the primary drying. Alternatively, the lyophilization can be conducted without a distinguished secondary drying step.

Abstract: A light-emitting substrate includes a substrate, a reflective layer, at least one first alignment mark disposed on the substrate, a plurality of support columns and a plurality of light-emitting devices. The reflective layer is disposed on the substrate, and the reflective layer has a plurality of openings and a plurality of installation openings. The plurality of openings include at least one first opening. A first alignment mark is exposed by a first opening. In at least one support column, an orthogonal projection of a support column on the substrate at least partially overlaps with an orthogonal projection of an opening on the substrate. The plurality of light-emitting devices are disposed on the substrate, and a light-emitting device is located in an installation opening in the reflective layer.

Abstract: Methods for stabilizing an Fc-containing protein preparation in an aqueous solution are provided herein. The disclosed methods can stabilize the Fc-containing protein in a drug product, especially for liquid formulations, by using phenol or benzyl alcohol as preservatives.

Abstract: The present disclosure provides a method for manufacturing an ultra-thin glass substrate, including: providing a large glass sheet including a plurality of to-be-cut glass substrates, each to-be-cut glass substrate including a bendable region and a non-bendable region arranged at two sides of the bendable region along a first direction; cutting each to-be-cut glass substrate along an edge of the bendable region to form two slits arranged opposite to each other; performing a double-sided thinning operation on the large glass sheet, and performing an edge etching operation on the edge of the bendable region; cutting each to-be-cut glass substrate along an edge of the non-bendable region through a laser to obtain a glass substrate; performing a chemical tempering operation on the glass substrate; and performing micro-etching treatment on a surface of the chemically-tempered glass substrate. The present disclosure further provides the ultra-thin glass substrate and a display device.

Abstract: The present inventions relate to methods of preparing highly concentrated monoclonal antibody (mAb) formulations, including screening and selection of excipients to include in mAb formulation. Excipients include amino acids, salts and polyols.

Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-4 receptor (hIL-4R). The formulations may contain, in addition to an anti-hIL-4R antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.

Abstract: The present disclosure provides pharmaceutical formulations comprising one or more antibodies or antigen-binding fragments thereof that bind to the cat allergen Fel d1. The formulations may contain, in addition to the anti-Fel d1 antibody, a buffer, a thermal stabilizer, a viscosity reducer, and a surfactant. In one aspect, co-formulations comprising two anti-Fel d1 antibodies are provided that have acceptable stability and optimal viscosity.

Abstract: Biopharmaceutical compositions and drug products disclosed herein exhibit reduced amounts of subvisible particle formation. Compositions and drug products disclosed herein comprise a protein and a surfactant or stabilizer including high percentage amounts of a long-chain fatty acid ester. Also disclosed herein are methods of preparing and storing such compositions and drug products.

Abstract: A light-emitting substrate includes: a substrate having a first surface; a plurality of light-emitting devices located on the first surface; a reflective layer located on the first surface, the reflective layer having a plurality of first openings, a light-emitting device being located in a first opening; a plurality of dam structures located on the reflective layer, each dam structure having a second opening, an orthogonal projection of a first opening on the substrate being located within an orthogonal projection of the second opening on the substrate; and a plurality of first encapsulation structures located on a side of the plurality of light-emitting devices away from the substrate, a first encapsulation structure covering at least one light-emitting device, the orthogonal projection of the second opening on the substrate being located within an orthographic projection of the first encapsulation structure on the substrate.

Abstract: A method for reducing auto-dosing fluctuation of a washing machine equipped with an automatic dosing device, by using a liquid detergent with a relatively low high-shear viscosity. A cleaning system including a washing machine equipped with an auto-dosing device, in combination with a liquid detergent characterized by a relative low high-shear viscosity.

Abstract: The present disclosure provides a stable protein composition containing a surfactant and having less than 400 subvisible particles of 10 microns or greater diameter per container, or less than 10,000 subvisible particles of 2 microns or greater per container. A method of manufacturing such a stable protein composition is disclosed, which includes a unit of operation that removes or decreases an esterase activity that degrades the surfactant. The unit of operation may be hydrophobic interaction chromatography or filtration, mixed mode chromatography, or the like.

Abstract: Lyophilization methods for preparing protein formulations for long-term storage at room temperature or improved stability at refrigeration storage are provided. Specifically, the present application provides lyophilization methods to obtain a target percentage of residual moisture of a lyophilized product, such as 3-5% residual moisture. The secondary drying of the lyophilization can be conducted under controlling rate of desorption under a temperature which is similar to the shelf temperature of the primary drying. Alternatively, the lyophilization can be conducted without a distinguished secondary drying step.

Abstract: A method for reducing auto-dosing fluctuation of a washing machine equipped with an automatic dosing device, by using a liquid detergent with a relatively low high-shear viscosity. A cleaning system including a washing machine equipped with an auto-dosing device, in combination with a liquid detergent characterized by a relative low high-shear viscosity.

Abstract: The disclosure provides a to-be-tested object extraction apparatus and a nucleic acid testing integrated machine with the to-be-tested object preparation apparatus.

Abstract: The disclosure provides a to-be-tested object processing apparatus and a nucleic acid testing integrated machine with the to-be-tested object processing apparatus.

Abstract: Provided is a sample analysis device, including: a housing, a reagent preparation apparatus, a sample processing apparatus, and an analysis apparatus. A first independent space, a second independent space and a third independent space are sequentially arranged in the housing at intervals. The reagent preparation apparatus is arranged in the first independent space. The sample processing apparatus is arranged in the second independent space, a first conveying channel is arranged between the reagent preparation apparatus and the sample processing apparatus, a first switching piece is arranged at the first conveying channel, and the first switching piece has a first opening state and a first closing state.

Abstract: Biopharmaceutical compositions and drug products disclosed herein exhibit reduced amounts of subvisible particle formation. Compositions and drug products disclosed herein comprise a protein and a surfactant or stabilizer including high percentage amounts (e.g., at least 97%) of a long-chain fatty acid ester. Also disclosed herein are methods of preparing and storing such compositions and drug products.

Abstract: Pharmaceutical formulations comprising an antibody that specifically binds to human interleukin-4 receptor alpha (hIL-4R?) are provided. The formulations may contain, in addition to an anti-IL-4R? antibody, one or more buffers, at least one amino acid, at least one sugar, and a surfactant comprising a polysorbate, polyethylene glycol or a poloxamer. Methods for producing pharmaceutical formulations with reduced lipase activity are also provided, which may include subjecting a drug substance to anion exchange chromatography in acidic conditions, agitation stress, heat stress, and additional ion exchange or size exclusion chromatography. In one aspect, the pharmaceutical formulations do not have appreciable subvisible particle formation in the presence of lipase, and exhibit a substantial degree of antibody stability during storage and after being subjected to thermal and other physical stresses.

Abstract: The present disclosure provides a co-formulation that includes an antibody that binds specifically to C5 and a C5 iRNA which is a glycoconjugate that includes a ligand having terminal N-Acetylgalactosamine (GalNAc) residues and/or N-acetylglucosamine (GlcNAc) residues. Methods for reducing degradation of glycoconjugate RNA by beta-hexosaminidase enzyme are also provided. The present disclosure also includes methods for treating or preventing a C5-associated disease or disorder by administering one or more doses of an anti-C5 antibody or antigen-binding fragment thereof in combination with one or more doses of a C5 iRNA; preferably wherein the anti-C5 antibody or fragment and the C5 iRNA are in a co-formulation. The present disclosure also includes dosing regimens for treating C5-associated disease or disorder with a combination of anti-C5 antibody and C5 iRNA in subjects that either are treatment naïve or are switching from a previous C5 inhibitor therapy.

Abstract: The present invention relates to a platform door control apparatus based on a double 2-vote-2 architecture, including a security communication and logic processing module, a driver collection module, and a maintenance module, the security communication and logic processing module is separately connected to the driver collection module and the maintenance module, and both the security communication and logic processing module and the driver collection module are devices using the double 2-vote-2 architecture. Compared with the prior art, the present invention has the following advantages of effectively improving linkage efficiency of a signal system and a platform door system, and the like.